{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T02:44:45Z","timestamp":1781664285234,"version":"3.54.5"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.ygyno.2018.03.002","type":"journal-article","created":{"date-parts":[[2018,3,18]],"date-time":"2018-03-18T14:51:10Z","timestamp":1521384670000},"page":"283-290","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["The role of adjuvant therapy in stage IA serous and clear cell uterine cancer: A multi-institutional pooled analysis"],"prefix":"10.1016","volume":"149","author":[{"given":"X. Melody","family":"Qu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram M.","family":"Velker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice S.","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Elshaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwa","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie A.","family":"Logie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas C.","family":"Mendez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis J.","family":"van der Putten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elysia K.","family":"Donovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan R.","family":"Munkarah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ericka M.","family":"Wiebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Parra-Herran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Warner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander V.","family":"Louie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"D'Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2018.03.002_bb0005","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2018.03.002_bb0010","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/sj.bjc.6603012","article-title":"Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers","volume":"94","author":"Hamilton","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2018.03.002_bb0015","series-title":"SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988\u20132001, Patient and Tumor Characteristics. Cancer of the Corpus Uteri","author":"Ries","year":"2007"},{"key":"10.1016\/j.ygyno.2018.03.002_bb0020","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ygyno.2009.06.011","article-title":"Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review","volume":"115","author":"Boruta","year":"2009","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2018.03.002_bb0025","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/j.1525-1438.2007.01082.x","article-title":"Is adjuvant therapy necessary for stage IA and IB uterine papillary serous carcinoma and clear cell carcinoma after surgical staging?","volume":"18","author":"Kwon","year":"2008","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2018.03.002_bb0030","author":"National Comprehensive Cancer Network"},{"key":"10.1016\/j.ygyno.2018.03.002_bb0035","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/IGC.0000000000000643","article-title":"Role of adjuvant therapy for stage IA serous and clear cell uterine cancer: is observation a valid strategy?","volume":"26","author":"Velker","year":"2016","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2018.03.002_bb0040","series-title":"The GEC ESTRO Handbook of Brachytherapy","first-page":"14","author":"Hoskin","year":"2016"},{"key":"10.1016\/j.ygyno.2018.03.002_bb0045","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1002\/cncr.24247","article-title":"Platinum\/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma","volume":"115","author":"Fader","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2018.03.002_bb0050","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ygyno.2005.06.012","article-title":"Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy","volume":"98","author":"Kelly","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.03.002_bb0055","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ygyno.2009.07.030","article-title":"An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC)","volume":"115","author":"Fader","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.03.002_bb0060","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ygyno.2004.08.030","article-title":"Patients with uterine papillary serous cancers may benefit from adjuvant platinum-based chemoradiation","volume":"95","author":"Kelly","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.03.002_bb0065","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ygyno.2008.10.006","article-title":"Concurrent carboplatin\/paclitaxel and intravaginal radiation in surgical stage I-II serous endometrial cancer","volume":"112","author":"Alektiar","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.03.002_bb0070","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ygyno.2012.07.112","article-title":"Five-year outcomes of adjuvant carboplatin\/paclitaxel chemotherapy and intravaginal radiation for stage I\u2013II papillary serous endometrial cancer","volume":"127","author":"Kiess","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.03.002_bb0075","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1097\/IGC.0b013e31822e7588","article-title":"Role of adjuvant chemotherapy in patients with early stage uterine papillary serous cancer","volume":"21","author":"Mahdavi","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2018.03.002_bb0080","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1200\/JCO.2004.00.7617","article-title":"Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study","volume":"24","author":"Randall","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.03.002_bb0085","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1016\/j.ejca.2010.06.002","article-title":"Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer\u2014results from two randomised studies","volume":"46","author":"Hogberg","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2018.03.002_bb0090","doi-asserted-by":"crossref","first-page":"5502","DOI":"10.1200\/JCO.2017.35.15_suppl.5502","article-title":"Final results of the international randomized PORTEC-3 trial of adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer","volume":"35","author":"de Boer","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.03.002_bb0095","series-title":"A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel\/Carboplatin Chemotherapy in Patients With High-risk, Early-stage Endometrial Cancer: A Gynecology Oncology Group study","author":"Randall","year":"2017"},{"key":"10.1016\/j.ygyno.2018.03.002_bb0100","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S0140-6736(09)62163-2","article-title":"Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial","volume":"375","author":"Nout","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2018.03.002_bb0105","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1701-2163(15)30966-X","article-title":"The role of surgery in endometrial cancer","volume":"35","author":"Giede","year":"2013","journal-title":"J. Obstet. Gynaecol. Can."},{"key":"10.1016\/j.ygyno.2018.03.002_bb0110","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1093\/jnci\/djn397","article-title":"Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial","volume":"100","author":"Benedetti Panici","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2018.03.002_bb0115","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(08)61766-3","article-title":"Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study","volume":"373","author":"Astec study group","year":"2009","journal-title":"Lancet"},{"issue":"Suppl. 6","key":"10.1016\/j.ygyno.2018.03.002_bb0120","article-title":"Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Colombo","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2018.03.002_bb0125","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.ygyno.2003.08.027","article-title":"Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy","volume":"91","author":"Huh","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.03.002_bb0130","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/IGC.0000000000000072","article-title":"Does positive peritoneal cytology not affect the prognosis for stage I uterine endometrial cancer?: the remaining controversy and review of the literature","volume":"24","author":"Shiozaki","year":"2014","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2018.03.002_bb0135","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.ygyno.2016.10.016","article-title":"Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: an NRG Oncology\/Gynecologic Oncology Group ancillary analysis","volume":"143","author":"Fader","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.03.002_bb0140","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/IGC.0000000000000838","article-title":"Extrauterine spread, adjuvant treatment, and prognosis in noninvasive uterine papillary serous carcinoma of the endometrium: a retrospective multicenter study","volume":"27","author":"Boyraz","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2018.03.002_bb0145","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ygyno.2007.01.041","article-title":"Outcomes in surgical stage I uterine papillary serous carcinoma","volume":"105","author":"Havrilesky","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.03.002_bb0150","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ygyno.2013.11.002","article-title":"Population-based treatment and outcomes of Stage I uterine serous carcinoma","volume":"132","author":"van der Putten","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.03.002_bb0155","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.ygyno.2014.12.034","article-title":"Adjuvant vaginal brachytherapy decreases the risk of vaginal recurrence in patients with stage I non-invasive uterine papillary serous carcinoma. A multi-institutional study","volume":"136","author":"Mahdi","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.03.002_bb0160","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ygyno.2015.01.544","article-title":"Impact of adjuvant chemotherapy and pelvic radiation on pattern of recurrence and outcome in stage I non-invasive uterine papillary serous carcinoma. A multi-institution study","volume":"137","author":"Mahdi","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.03.002_bb0165","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1177\/1933719112459218","article-title":"The clinical relevance of rising CA-125 levels within the normal range in patients with uterine papillary serous cancer","volume":"20","author":"Frimer","year":"2013","journal-title":"Reprod. Sci."},{"key":"10.1016\/j.ygyno.2018.03.002_bb0170","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/IGC.0000000000000318","article-title":"Identification of a preoperative predictive factor for lymph node metastasis in uterine papillary serous carcinoma: long-term results from a single institution","volume":"25","author":"Baek","year":"2015","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2018.03.002_bb0175","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/bjc.2015.190","article-title":"A clinically applicable molecular-based classification for endometrial cancers","volume":"113","author":"Talhouk","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2018.03.002_bb0180","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Cancer Genome Atlas Research N","year":"2013","journal-title":"Nature"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825818301720?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825818301720?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,12]],"date-time":"2019-10-12T22:31:22Z","timestamp":1570919482000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825818301720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S0090825818301720"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2018.03.002","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of adjuvant therapy in stage IA serous and clear cell uterine cancer: A multi-institutional pooled analysis","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2018.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}